問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1449Cases

2020-03-17 - 2024-05-02

Phase III

A multicenter, randomized, double-blind, parallelgroup, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >= 40%. (LVEF >= 40%)

  • Condition/Disease

    heart failure

  • Test Drug

    Finerenone/ BAY 94-8862

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2020-10-16 - 2025-06-27

Others

An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies

  • Condition/Disease

    non-metastatic castrate-resistant prostate cancer (nmCRPC)

  • Test Drug

    BAY 1841788

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2018-12-01 - 2021-08-31

Phase II

A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis

  • Condition/Disease

    Endometriosis

  • Test Drug

    Vilaprisan (BAY 1002670)

Participate Sites
6Sites

Not yet recruiting3Sites

Terminated3Sites

2012-06-29 - 2014-11-28

Phase III

A multi-center, open, uncontrolled phase 3 study to investigate the efficacy and safety of a 4-phasic oral contraceptive SH T00658ID containing estradiol valerate and dienogest in a 28-day regimen for 13 cycles in healthy female subjects

  • Condition/Disease

    oral contraceptive

  • Test Drug

    BAY 86-5027

Participate Sites
6Sites

Terminated6Sites

2009-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-02-10 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2008-12-15 - 2012-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-09-21 - 2021-10-14

Phase III

A Randomized, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

  • Condition/Disease

    Uterine Fibroids

  • Test Drug

    Vilaprisan (BAY 1002670)

Participate Sites
8Sites

Terminated8Sites

2018-04-30 - 2022-10-31

Phase II/III

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Condition/Disease

    FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Test Drug

    BAY 1163877

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

1 134 135 136 137 138 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB